Phase I
As the number of diagnosed cases of COVID-19 continue to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization last week. Here’s a biopharma industry overview as of late March 16.
The company disclosed that the U.S. Food and Drug Administration placed a partial clinical hold on its Phase I trial for non-Hodgkin lymphoma due to a safety concern.
It was a relatively quiet week for clinical trial announcements. Here’s a look.
The stated cause of the suspension of enrollment was the occurrence of two intrathecal catheter-related infections that weren’t related to the drug.
As the coronavirus outbreak that causes COVID-19 escalates, biopharma companies and government agents are working quickly to develop and test a vaccine, although most estimates are it will take 12 to 18 months before it could get to market.
Life sciences companies from across the globe provide updates on their businesses and pipelines.
In addition, the company’s chief scientific officer, Seth Ettenberg, has resigned.
The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Abivax SA announced dosing of the first patient in a U.S. Phase 1/2 clinical trial of ABX196 to treat patients with hepatocellular carcinoma, the most common form of liver cancer..
A federal judge has ruled that a decade’s worth of unpublished clinical trial data from drug companies, universities and other agencies involved, must now be made public.
PRESS RELEASES